Answers are grounded in this paper and cite their sources.
A highly robust and high-throughput liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed and validated for the quantification of apalutamide in human plasma. Chromatographic separation was achieved on a ZORBAX Eclipse XDB-C18 column via gradient elution, using a mobile phase comprising acetonitrile and 0.1% formic acid with 5-mM ammonium acetate. The method featured a broad linear dynamic range of 1.00-2500 ng/mL. Furthermore, the assay exhibited exceptional selectivity and matrix resistance across normal, hyperlipidemic, and hemolyzed blank matrices. Validation results demonstrated high reliability: Intra-batch and inter-batch precision (CV) were ≤ 6.6%, with accuracies (RE) strictly within ±3.4%. Mean extraction recoveries for apalutamide and the internal standard exceeded 102%. This method was applied to evaluate the pharmacokinetics of a single 60-mg apalutamide dose in 60 healthy Chinese male volunteers under both fasting and fed conditions. The 90% confidence intervals for the geometric mean ratios of all primary pharmacokinetic parameters fell within the regulatory 80%-125% equivalence limits. Consequently, the test and reference formulations were confirmed to be bioequivalent. The 60-mg oral dosage was well tolerated by all subjects, with no serious adverse events or adverse events exceeding Grade 1 observed during the trial.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: